Abstract
This chapter will focus on two genetic syndromes affecting hypothalamic function that typically present in childhood, Prader-Willi syndrome, and congenital optic nerve hypoplasia.
Prader-Willi syndrome (PWS) is a complex and challenging rare disorder resulting from the absence of gene expression on the paternal chromosome 15q11.2–q13. First described in 1956 as a medical syndrome, the chromosome 15 deletion was discovered in 1981. PWS is a spectrum disorder with a complex phenotype. The universal hallmark is hypotonia with decreased foetal activity noted during pregnancy. Most neonates are born with a lack of suck and respiratory irregularities. They are sleepy and seldom cry. Hypotonia and failure to thrive in infancy evolve into rapid weight gain in early childhood often with insatiable appetite and food seeking; this will lead to profound life-threatening obesity if not well managed at home and in school. Hypothalamic impairments complicate day-to-day life—high pain tolerance, temperature dysregulation, sleepiness, and constant drive to eat. Pituitary deficiencies of growth hormone and GnRH require skilled endocrine care throughout the lifespan. Children with PWS are at risk for respiratory crises from central apnoea and hypotonia with poor ventilatory effort in infancy and aspiration from impaired swallowing motility. Intellectual abilities span a wide spectrum although many children are successful in mainstream classrooms. Unique behavioural patterns including perseveration, skin picking, anxiety, and difficulty with task switching are common. With early diagnosis and intervention, developmental progress, health, and family stress can be significantly improved. Families need diagnosis-specific interventions with specialized medical care throughout the lifespan. Researchers are expanding understanding of PWS. Children born in the past two decades enjoy improved quality of life over previous generations. Treatment remains symptom driven, with no cure for the gene deletion.
Congenital optic nerve hypoplasia is correlated with pituitary dysfunction and developmental brain abnormalities. Nystagmus in infancy should be promptly assessed in the endocrine setting as pituitary deficiencies can include life-threatening hypoglycaemia and shock. Newborn screening programmes designed for congenital hypothyroidism seldom detect thyroid stimulating hormone (TSH) deficiency leaving these babies at high risk of hypothyroidism at the most critical time. Visual impairment ranges from unilateral visual field defects to bilateral complete blindness; pituitary deficiencies can be complete deficiencies of all hormones with prenatal onset, or development of insufficiencies over time. Brain abnormalities noted on magnetic resonance imaging (MRI) have relevance in predicting developmental and intellectual challenges, which occur in a wide spectrum. Endocrine nurses have a critical role in supporting and educating these families, and in helping them understand the unique impact of visual impairment on the child’s development and behaviour.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ACTH:
-
Adrenocorticotropic hormone
- ADH:
-
Antidiuretic hormone
- APGAR:
-
Appearance-Pulse-Grimace-Activity-Respiration
- BMI:
-
Body mass index
- cm:
-
Centimetre
- DNA:
-
Deoxyribonucleic acid
- FDA:
-
Food and Drug Administration
- FISH:
-
Florence in situ hybridization
- FPWR:
-
Foundation for Prader-Willi Research
- GH:
-
Growth hormone
- GnRH:
-
Gonadotropin releasing hormone
- hCG:
-
Human chorionic gonadotropin
- IGF-1:
-
Insulin like growth factor 1
- IPWSO:
-
International Prader-Willi Syndrome Organization
- kg:
-
Kilogram
- mg:
-
Milligram
- MRI:
-
Magnetic resonance imaging
- NIH:
-
National Institutes of Health
- ONH:
-
Optic nerve hypoplasia
- OT:
-
Occupational therapy
- PC1:
-
Prohormone convertase
- PT:
-
Physical therapy
- SOD:
-
Septo optic dysplasia
- TSH:
-
Thyroid stimulating hormone
- USA:
-
United States of America
References
Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Investig. 2015;38(12):1249–63.
Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-Koelega AC. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab. 2013;98(10):4013–22.
Bakker NE, Wolffenbuttel KP, Looijenga LH, Hokken-Koelega AC. Testes in infants with Prader-Willi syndrome: human chorionic gonadotropin treatment, surgery and histology. J Urol. 2015;193(1):291–8.
Borchert M. Reappraisal of the optic nerve hypoplasia syndrome. J Neuroophthalmol. 2012;32(1):58–67. https://doi.org/10.1097/WNO.0b013e31824442b8.
Burnett LC, LeDuc CA, Sulsona CR, Paull D, Rausch R, Eddiry S, Carli JF, Morabito MV, Skowronski AA, Hubner G, Zimmer M, Wang L, Day R, Levy B, Fennoy I, Dubern B, Poitou C, Clement K, Butler MG, Rosenbaum M, Salles JP, Tauber M, Driscoll DJ, Egli D, Leibel RL. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. J Clin Invest. 2017;127(1):293–305.
Butler MG, Lee J, Cox DM, Manzardo AM, Gold JA, Miller JL, Roof E, Dykens E, Kimonis V, Driscoll DJ. Growth charts for Prader-Willi syndrome during growth hormone treatment. Clin Pediatr (Phila). 2016a;55(10):957–74.
Butler MG, Manzardo AM, Forster JL. Prader-Willi syndrome: clinical genetics and diagnostic aspects with treatment approaches. Curr Pediatr Rev. 2016b;12(2):136–66.
Cemeroglu AP, Coulas T, Kleis L. Spectrum of clinical presentations andendocrinological findings of patients with septo-optic dysplasia: a retrospective study. J Pediatr Endocrinol Metab. 2015;28(9–10):1057–63.
Deal CL, Tony M, Höybye C, Allen DB, Tauber M, Christiansen JS. 2011 Growth Hormone in Prader-Willi Syndrome Clinical Care Guidelines Workshop Participants. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013a;98(6):E1072–87.
Deal C, Hasselmann C, Pfäffle RW, Zimmermann AG, Quigley CA, Child CJ, Shavrikova EP, Cutler GB Jr, Blum WF. Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growthhormone deficiency: data from an International Observational Study. Horm Res Paediatr. 2013b;79(5):283–92.
Dykens EM, Roof E, Hunt-Hawkins H. Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome. J Child Psychol Psychiatry. 2017;58(1):64–74.
Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. Int J Pediatr Endocrinol. 2013;2013(1):14.
Garcia-Filion P, Borchert M. Optic nerve hypoplasia syndrome: a review of theepidemiology and clinical associations. Curr Treat Options Neurol. 2013;15(1):78–89.
Gross RD, Gisser R, Cherpes G, Hartman K, Maheshwary R. Subclinical dysphagia in persons with Prader-Willi syndrome. Am J Med Genet A. 2017;173(2):384–94.
Irizarry KA, Miller M, Freemark M, Haqq AM. Prader Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Pediatr Infect Dis. 2016;63(1):47–77.
Jutley-Neilson J, Harris G, Kirk J. The identification and measurement ofautistic features in children with septo-optic dysplasia, optic nerve hypoplasia and isolated hypopituitarism. Res Dev Disabil. 2013;34(12):4310–8.
Manzardo AM, Johnson L, Miller JL, Driscoll DJ, Butler MG. Higher plasma orexin a levels in children with Prader-Willi syndrome compared with healthy unrelated sibling controls. Am J Med Genet A. 2016;170(9):2328–33.
McCabe MJ, Dattani MT. Genetic aspects of hypothalamic and pituitary gland development. Handb Clin Neurol. 2014;124:3–15.
McCandless SE. Committee on Genetics. Clinical report—health supervision for children with Prader-Willi syndrome. Pediatrics. 2011;127(1):195–204.
Miller JL, Tamura R, Butler MG, Kimonis V, Sulsona C, Gold JA, Driscoll DJ. Oxytocin treatment in children with Prader-Willi syndrome: a double-blind, placebo-controlled, crossover study. Am J Med Genet A. 2017;173(5):1243–50.
Ryabets-Lienhard A, Stewart C, Borchert M, Geffner ME. The optic nerve hypoplasia spectrum: review of the literature and clinical guidelines. Adv Pediatr Infect Dis. 2016;63(1):127–46.
Signorini SG, Decio A, Fedeli C, Luparia A, Antonini M, Bertone C, Misefari W, Ruberto G, Bianchi PE, Balottin U. Septo-optic dysplasia in childhood: the neurological, cognitive and neuro-ophthalmological perspective. Dev Med Child Neurol. 2012;54(11):1018–24.
Tan HL, Urquhart DS. Respiratory complications in children with Prader-Willi syndrome. Paediatr Respir Rev. 2017;22:52–9.
Tauber M, Boulanouar K, Diene G, Çabal-Berthoumieu S, Ehlinger V, Fichaux-Bourin P, Molinas C, Faye S, Valette M, Pourrinet J, Cessans C, Viaux-Sauvelon S, Bascoul C, Guedeney A, Delhanty P, Geenen V, Martens H, Muscatelli F, Cohen D, Consoli A, Payoux P, Arnaud C, Salles JP. The use of oxytocin to improve feeding and social skills in infants with Prader-Willi syndrome. Pediatrics. 2017;139(2).
Vitale SA. Parent recommendations for family functioning with Prader-Willi syndrome: a rare genetic cause of childhood obesity. J Pediatr Nurs. 2016;31(1):47–54.
Whittington J, Holland A. Neurobehavioral phenotype in Prader-Willi syndrome. Am J Med Genet C Semin Med Genet. 2010;154C(4):438–47.
Key Reading
Irizarry KA, Miller M, Freemark M, Haqq AM. Prader-Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Pediatr. 2016;63(1):47–77.
Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. Int J Pediatr Endocrinol. 2013;2013(1):14.
McCandless SE. Committee on Genetics. Clinical report—health supervision for children with Prader-Willi syndrome. Pediatrics. 2011;127(1):195–204.
Borchert M. Reappraisal of the optic nerve hypoplasia syndrome. J Neuroophthalmol. 2012;32(1):58–67.
Garcia-Filion P, Borchert M. Optic nerve hypoplasia syndrome: a review of the epidemiology and clinical associations. Curr Treat Options Neurol. 2013;15(1):78–89.
Ryabets-Lienhard A, Stewart C, Borchert M, Geffner ME. The optic nerve hypoplasia spectrum: review of the literature and clinical guidelines. Adv Pediatr. 2016;63(1):127–46.
Web Resources for Families
Acknowledgements
With special thanks to Kathy Clark, Medical Coordinator for Prader-Willi Syndrome Association (USA), for including information about the Patient Advocacy Groups: Prader-Willi Syndrome Association (USA) (https://www.pwsausa.org), Foundation for Prader-Willi Research (FPWR) (https://www.fpwr.org), and the International Prader-Willi Syndrome Organization (IPWSO) (https://www.ipwso.org).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Clark, K. (2019). Genetic Syndromes Presenting in Childhood Affecting Hypothalamic Function. In: Llahana, S., Follin, C., Yedinak, C., Grossman, A. (eds) Advanced Practice in Endocrinology Nursing. Springer, Cham. https://doi.org/10.1007/978-3-319-99817-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-99817-6_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99815-2
Online ISBN: 978-3-319-99817-6
eBook Packages: MedicineMedicine (R0)